ES2564252T3 - Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos - Google Patents

Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos Download PDF

Info

Publication number
ES2564252T3
ES2564252T3 ES11745672.3T ES11745672T ES2564252T3 ES 2564252 T3 ES2564252 T3 ES 2564252T3 ES 11745672 T ES11745672 T ES 11745672T ES 2564252 T3 ES2564252 T3 ES 2564252T3
Authority
ES
Spain
Prior art keywords
seq
lcdr1
lcdr2
hcdr1
hcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11745672.3T
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2564252T3 publication Critical patent/ES2564252T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo monoclonal anti-N3pGlu Aß humano diseñado por ingeniería genética o fragmento de unión al antígeno del mismo, que comprende una región variable de cadena ligera (LCVR) y una región variable de cadena pesada (HCVR), en el que dicha LCVR comprende los polipéptidos LCDR1, LCDR2 y LCDR3, y HCVR comprende los polipéptidos HCDR1, HCDR2 y HCDR3 que se seleccionan entre: a) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYDFTRYYIN (SEC ID Nº 6), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGITVY (SEC ID Nº 9); b) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTRYYIN (SEC ID Nº 7), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGTTVY (SEC ID Nº 10); c) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTDYYIN (SEC ID Nº 40), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGETVY (SEC ID Nº 41); d) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLGS (SEC ID Nº 35), LCDR3 es VQGTHYPFT 5 (SEC ID Nº 5), HCDR1 es GYTFTRYYIN (SEC ID Nº 7), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGTTVY (SEC ID Nº 10); y e) LCDR1 es KSTRSLLYSRSKTYLN (SEC ID Nº 45), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTDYYIN (SEC ID Nº 40), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8), y HCDR3 es EGVTVY (SEC ID Nº 46).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES11745672.3T 2010-08-12 2011-08-09 Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos Active ES2564252T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12
US373026P 2010-08-12
PCT/US2011/046994 WO2012021469A1 (en) 2010-08-12 2011-08-09 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES2564252T3 true ES2564252T3 (es) 2016-03-21

Family

ID=44543826

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11745672.3T Active ES2564252T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
ES15196358.4T Active ES2664128T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
ES18150424T Active ES2764728T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES15196358.4T Active ES2664128T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
ES18150424T Active ES2764728T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos

Country Status (41)

Country Link
US (2) US8679498B2 (es)
EP (3) EP3339323B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN105111308B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK3339323T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2564252T3 (es)
FI (1) FIC20250038I1 (es)
FR (1) FR25C1055I1 (es)
GT (1) GT201300036A (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE028678T2 (es)
IL (2) IL285226B2 (es)
LT (3) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME03032B (es)
MX (2) MX342782B (es)
MY (2) MY163521A (es)
NL (1) NL301359I2 (es)
NO (2) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL2603523T3 (es)
PT (2) PT3339323T (es)
RS (3) RS59652B1 (es)
SG (2) SG187586A1 (es)
SI (3) SI2603523T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
CA2938129A1 (en) * 2014-02-03 2015-08-06 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
CA2954476C (en) 2014-07-10 2023-09-19 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
KR102777500B1 (ko) * 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
HK1257518A1 (zh) 2016-01-11 2019-10-25 Novartis Ag 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
TW201740954A (zh) * 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3496750A2 (en) * 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
JP2019530647A (ja) 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
SG11201903770UA (en) 2016-10-28 2019-05-30 H Lundbeck As Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI705975B (zh) * 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
LT3723807T (lt) 2017-12-14 2021-12-10 H. Lundbeck A/S Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
KR20260053095A (ko) * 2018-02-11 2026-04-20 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
MX2020009507A (es) * 2018-03-13 2020-10-22 Smivet B V Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
MA55491A (fr) * 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
IL301572A (en) * 2020-10-02 2023-05-01 Lilly Co Eli Methods for reducing the protein content of the host cell in protein purification processes
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
CN118139880A (zh) 2021-10-22 2024-06-04 伊莱利利公司 O-连接的n-乙酰葡糖胺水解酶(oga)抑制剂联合治疗
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
AU2022376940A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
AU2022376930A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
JP2025506411A (ja) 2022-02-03 2025-03-11 イーライ リリー アンド カンパニー アルツハイマー病の診断及び治療のための局所タウイメージング
AU2023309007A1 (en) 2022-07-21 2025-01-30 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228315A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025237397A1 (zh) * 2024-05-16 2025-11-20 江苏恒瑞医药股份有限公司 抗N3pGlu Aβ抗体及其医药用途
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
TW202607032A (zh) 2024-06-20 2026-02-16 瑞典商生物極公司 雙特異性結合分子
WO2026012421A1 (zh) * 2024-07-11 2026-01-15 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026055601A1 (en) 2024-09-09 2026-03-12 Eli Lilly And Company METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
AU2005217596B2 (en) * 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
EP2146746A4 (en) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
WO2009149487A2 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
EP3338795A1 (en) * 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
HUE037524T2 (hu) 2018-09-28
SG10201509330XA (en) 2015-12-30
MX355268B (es) 2018-04-11
CN103068848A (zh) 2013-04-24
CN105111308A (zh) 2015-12-02
ES2764728T3 (es) 2020-06-04
JP5980207B2 (ja) 2016-08-31
ME03032B (me) 2018-10-20
CR20130016A (es) 2013-03-21
JP2016179985A (ja) 2016-10-13
ECSP13012436A (es) 2013-03-28
BR112013004056B8 (pt) 2022-10-18
MY181969A (en) 2021-01-15
ES2664128T3 (es) 2018-04-18
PL3339323T3 (pl) 2020-05-18
CO6670526A2 (es) 2013-05-15
EA201270813A1 (ru) 2013-05-30
DOP2013000029A (es) 2013-03-15
MX2013001716A (es) 2013-10-28
PL2603523T3 (pl) 2016-07-29
FR25C1055I1 (fr) 2026-03-06
IL224030B (en) 2022-04-01
HRP20192233T1 (hr) 2020-03-06
CN105111308B (zh) 2019-03-12
DK3042917T3 (en) 2018-04-23
RS57026B1 (sr) 2018-05-31
RS59652B1 (sr) 2020-01-31
LT3042917T (lt) 2018-05-10
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
IL285226B2 (en) 2023-02-01
FIC20250038I1 (fi) 2025-12-18
ME02352B (me) 2016-06-20
CY1120144T1 (el) 2018-12-12
CL2013000390A1 (es) 2014-03-21
AU2011289629A1 (en) 2013-02-14
HK1180703A1 (zh) 2013-10-25
CY1122458T1 (el) 2021-01-27
PL3042917T3 (pl) 2018-07-31
PH12013500277A1 (en) 2017-04-21
WO2012021469A1 (en) 2012-02-16
AU2011289629B2 (en) 2014-07-03
EP3042917A1 (en) 2016-07-13
BR112013004056B1 (pt) 2022-05-17
SI2603523T1 (sl) 2016-04-29
RS54685B1 (sr) 2016-08-31
NO2025056I1 (no) 2025-12-11
MX342782B (es) 2016-10-12
NL301359I2 (nl) 2026-02-10
LT3339323T (lt) 2020-02-10
KR20130051989A (ko) 2013-05-21
GT201300036A (es) 2014-07-16
IL285226A (en) 2021-09-30
SI3042917T1 (en) 2018-04-30
NZ606095A (en) 2014-11-28
US8679498B2 (en) 2014-03-25
HUE028678T2 (en) 2016-12-28
US20130142806A1 (en) 2013-06-06
EP3339323A1 (en) 2018-06-27
EP3042917B1 (en) 2018-02-21
CA2805114A1 (en) 2012-02-16
PE20130817A1 (es) 2013-07-18
DK3339323T3 (da) 2020-01-20
JP2013536191A (ja) 2013-09-19
CN103068848B (zh) 2015-11-25
EP2603523B1 (en) 2016-01-27
DK2603523T3 (en) 2016-03-21
EA023021B1 (ru) 2016-04-29
PT3339323T (pt) 2020-01-14
HRP20160151T1 (hr) 2016-03-11
IL285226B (en) 2022-10-01
CA2805114C (en) 2017-12-05
LTPA2026504I1 (es) 2026-02-10
EP2603523A1 (en) 2013-06-19
SI3339323T1 (sl) 2019-12-31
JP6395755B2 (ja) 2018-09-26
US20140065138A1 (en) 2014-03-06
MA34461B1 (fr) 2013-08-01
NZ626665A (en) 2016-04-29
UA107600C2 (uk) 2015-01-26
PT3042917T (pt) 2018-05-02
EP3339323B1 (en) 2019-11-13
ZA201300437B (en) 2014-06-25
ME03661B (me) 2020-07-20
US8961972B2 (en) 2015-02-24
BR112013004056A2 (pt) 2020-08-04
MY163521A (en) 2017-09-15
HRP20180616T1 (hr) 2018-07-13
NO3042917T3 (es) 2018-07-21

Similar Documents

Publication Publication Date Title
ES2656000T3 (es) Anticuerpos frente a CGRP
MX342782B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141151A1 (es) Proteinas de union al antigeno cd27l
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
RU2013113933A (ru) Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
JP2018021031A5 (es)
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
PE20221337A1 (es) Anticuerpos trem2 y usos de estos
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)